Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for proton pump inhibitors
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite protonpumpinhibitor therapy: a randomised placebo-controlled trial o evaluate the efficacy and tolerability of add-on treatment with lesogaberan (AZD3355), a novel reflux inhibitor, in patients with persistent gastro-oesophageal reflux disease (GORD) symptoms despite protonpumpinhibitor (PPI) therapy.double-blind, placebo-controlled, randomised, parallel-group
Protonpumpinhibitor use and the antifracture efficacy of alendronate Protonpumpinhibitors (PPIs) are widely used in elderly patients and are frequently coadministered in users of oral bisphosphonates. Biologically, PPIs could affect the absorption of calcium, vitamin B(12), and bisphosphonates and could affect the osteoclast protonpump, thus interacting with bisphosphonate antifracture efficacy. Moreover, PPIs themselves have been linked to osteoporotic fractures.Population-based, national
The efficacy of protonpumpinhibitors for the treatment of asthma in adults: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Effect of concomitant use of clopidogrel and protonpumpinhibitors after percutaneous coronary intervention The aim of the present study was to analyze the effect of drug exposure patterns of clopidogrel and protonpumpinhibitors (PPIs) on the clinical outcomes after percutaneous coronary intervention (PCI). Previous analyses predominantly included discharge medications and did not explore the effect of the drug exposure patterns. We analyzed all-cause death, nonfatal myocardial infarction
Cost-Utility of Aspirin and ProtonPumpInhibitors for Primary Prevention Aspirin reduces myocardial infarction but increases gastrointestinal tract (GI) bleeding. Protonpumpinhibitors (PPIs) may reduce upper GI bleeding. We estimate the cost-utility of aspirin treatment with or without a PPI for coronary heart disease (CHD) prevention among men at different risks for CHD and GI bleeding.We updated a Markov model to compare costs and outcomes of low-dose aspirin plus PPI (omeprazole, 20 mg/d
Protonpumpinhibitors therapy and risk of hip fracture: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and protonpumpinhibitors: clinical effectiveness, safety, and cost-effectiveness Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and protonpumpinhibitors: clinical effectiveness, safety, and cost-effectiveness Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and protonpumpinhibitors: clinical effectiveness, safety, and cost-effectiveness CADTH Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and protonpumpinhibitors: clinical effectiveness, safety, and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2011 Authors' conclusions Limited evidence showed that celecoxib versus non-COX-2 selective non-steroidal
Protonpumpinhibitors versus histamine-2-receptor antagonists for the management of iatrogenic gastric ulcer after endoscopic mucosal resection or endoscopic submucosal dissection: a meta-analysis of randomized trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
ProtonPumpInhibitors 2.0 ProtonPumpInhibitors 2.0 – Clinical Correlations Search ProtonPumpInhibitors 2.0 November 26, 2010 5 min read By Mary C. Whitman, MD Faculty Peer Reviewed and are prescribed to over . Recently, new data has emerged that suggests that we should be more judicious in prescribing PPIs. In a recent development, the FDA announced that it will require new labeling of PPIs indicating that their use at high . This change was prompted, in part, , who took PPIs for at least (...) of protonpumpinhibitors. World J Gastroenterol. 2010. 16(19):2323-30. Katz MH. Failing the Acid Test: Benefits of ProtonPumpInhibitors May not justify the risks for many users. Arch Intern Med. 2010;170(9):747-748. Corley DA, Kubo A, Zhao W, Quesenberry C. ProtonPumpInhibitors and Histamine-2 Receptor Antagonists are Associated with Hip Fractures Among At-Risk Patients. Gastrolenterology 2010. March. Epub ahead of print. Reimer C, Sondergaard B, Hilsted L, Bytzer P. Proton-pumpinhibitor therapy
Medications (NSAIDs, statins, protonpumpinhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett`s esophagus Limited evidence suggests that protonpumpinhibitors (PPI), nonsteroidal anti-inflammatory drugs (NSAID)/aspirin, and statins may be associated with a low risk of esophageal neoplasia. However, the possible effect these medications may have on the risk of esophageal adenocarcinoma (EAC) in patients with existing Barrett's esophagus (BE) is unclear.We conducted
Clopidogrel (Plavix) and ProtonPumpInhibitors: An Update on the Potential Drug Interaction Clopidogrel (Plavix®) and ProtonPumpInhibitors: An Update on the Potential Drug Interaction – Clinical Correlations Search Clopidogrel (Plavix®) and ProtonPumpInhibitors: An Update on the Potential Drug Interaction July 28, 2010 5 min read By Antony Q. Pham, Pharm.D. and Reena M. Tejura, Pharm.D. Faculty Peer Reviewed Recent publications have described a potential drug interaction between (...) clopidogrel (Plavix®) and protonpumpinhibitors (PPIs). Several retrospective studies have concluded that the use of PPIs can lower the effectiveness of clopidogrel and as a result, increase the possibility of cardiovascular events. Limited data from prospective trials have yet to show a clinical significance from this potential interaction. The Food and Drug Administration (FDA) released an early communication about the ongoing safety review of clopidogrel and omeprazole on January 26, 2009. Over
Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and protonpumpinhibitors in patients who received percutaneous coronary intervention Recent studies have suggested that protonpumpinhibitors (PPIs) might reduce the inhibitory effect of clopidogrel on platelet aggregation, possibly through inhibition of the hepatic cytochrome P450 2C19 (CYP2C19) isoenzyme. The prevalence of CYP2C19 loss-of-function alleles is much greater among East Asians than among other
Protonpumpinhibitors and risk for recurrent Clostridium difficile infection Protonpumpinhibitors (PPIs) are widely used gastric acid suppressants, but they are often prescribed without clear indications and may increase risk of Clostridium difficile infection (CDI). We sought to determine the association between PPI use and the risk of recurrent CDI.Retrospective, cohort study using administrative databases of the New England Veterans Healthcare System from October 1, 2003, through (...) determined that the adjusted HR of recurrent CDI was greater in those exposed to PPIs during treatment (1.42; 95% confidence interval [CI], 1.11-1.82). Risks among exposed patients were highest among those older than 80 years (HR, 1.86; 95% CI, 1.15-3.01) and those receiving antibiotics not targeted to C difficile during follow-up (HR, 1.71; 95% CI, 1.11-2.64). [corrected]Protonpumpinhibitor use during incident CDI treatment was associated with a 42% increased risk of recurrence. Our findings warrant
Protonpumpinhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women`s Health Initiative Protonpumpinhibitor (PPI) medications have been inconsistently shown to be associated with osteoporotic fractures. We examined the association of PPI use with bone outcomes (fracture, bone mineral density [BMD]).This prospective analysis included 161 806 postmenopausal women 50 to 79 years old, without history of hip fracture, enrolled in the Women's
WITHDRAWN: Protonpumpinhibitor treatment for acute peptic ulcer bleeding. Randomised controlled trials (RCTs) evaluating the clinical effect of protonpumpinhibitors (PPIs) in peptic ulcer (PU) bleeding yield conflicting results.To evaluate the efficacy of PPIs in acute bleeding from PU using evidence from RCTs.We searched CENTRAL, The Cochrane Library (Issue 4, 2004), MEDLINE (1966 to November 2004), EMBASE (1980 to November 2004), proceedings of major meetings to November 2004
Impact of protonpumpinhibitors on benign anastomotic stricture formations after esophagectomy and gastric tube reconstruction: results from a randomized clinical trial The primary aim of this study was to evaluate if the use of protonpumpinhibitors (PPIs) reduced the prevalence of benign anastomotic strictures after uncomplicated esophagectomies with gastric tube reconstruction and circular stapled anastomoses.Benign anastomotic strictures are associated with anastomotic leaks or conduit
ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of ProtonPumpInhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID nature publishing group the red section 2533 Writing Committee Members Neena S. Abraham, MD, FACG, Chair*; Mark A. Hlatky, MD, FACC, FAHA, Vice Chair† Elliott M. Antman, MD, FACC, FAHA‡; Deepak L. Bhatt, MD, MPH, FACC, FAHA† David J. Bjorkman (...) KW , Quigley EM, Scheiman J, Sper - ling LS, Tomaselli GF (. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of protonpumpinhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2010;105:2533–2549; doi:10.1038/ajg.2010.445. This article has been copublished in the Journal of the American College of Cardiology and Circulation. Copies
ProtonPumpInhibitors for Acute Upper GI Bleeding ProtonPumpInhibitors for Acute Upper GI Bleeding – TheNNTTheNNT ProtonPumpInhibitors (PPIs) Given for Acute Upper Gastrointestinal Bleeding Given Prior to Endoscopic Diagnosis No benefit found In Summary, for those who took the PPI: Benefits in NNT 100% saw no benefit 0% were helped by being saved from death, needing surgery, preventing repeat bleeding None were helped (life saved, preventing surgery, prevent repeat bleeding) Harms in NNT (...) gastrointestinal bleeding is a potentially life threatening condition that can demand aggressive intervention from the emergency physicians. Although bleeding can originate in any area above the ligament of Treitz, the majority of bleeding is from a peptic ulcer , . Protonpumpinhibitors (PPIs) work by reducing gastric acid secretion, neutralizing gastric pH, increasing clot formation and decreasing clot lysis . Intravenous protonpumpinhibitors have traditionally been used after endoscopic hemostasis